Titre : Paralysie pseudobulbaire

Paralysie pseudobulbaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes", "headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-02", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Paralysie", "url": "https://questionsmedicales.fr/mesh/D010243", "about": { "@type": "MedicalCondition", "name": "Paralysie", "code": { "@type": "MedicalCode", "code": "D010243", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.592.636" } } }, "about": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire", "alternateName": "Pseudobulbar Palsy", "code": { "@type": "MedicalCode", "code": "D020828", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Kenjiro Kunieda", "url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda", "affiliation": { "@type": "Organization", "name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN." } }, { "@type": "Person", "name": "Tomohisa Ohno", "url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno", "affiliation": { "@type": "Organization", "name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Ichiro Fujishima", "url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima", "affiliation": { "@type": "Organization", "name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Victor Kekere", "url": "https://questionsmedicales.fr/author/Victor%20Kekere", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } }, { "@type": "Person", "name": "Patrice Fouron", "url": "https://questionsmedicales.fr/author/Patrice%20Fouron", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Menopausal hormone therapy and dementia: nationwide, nested case-control study.", "datePublished": "2023-06-28", "url": "https://questionsmedicales.fr/article/37380194", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmj-2022-072770" } }, { "@type": "ScholarlyArticle", "name": "ICOS gene polymorphisms in systemic lupus erythematosus: A case-control study.", "datePublished": "2023-06-20", "url": "https://questionsmedicales.fr/article/37338463", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/iji.12625" } }, { "@type": "ScholarlyArticle", "name": "Endometriosis features and dienogest tolerability in women with depression: a case-control study.", "datePublished": "2023-05-03", "url": "https://questionsmedicales.fr/article/37132337", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13625187.2023.2199899" } }, { "@type": "ScholarlyArticle", "name": "The effect of environmental factors on precocious puberty in children: a case-control study.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37127587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12887-023-04013-1" } }, { "@type": "ScholarlyArticle", "name": "Neonatal Group B Streptococcal Infection in Australia: A Case-control Study.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36929884", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/INF.0000000000003881" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Manifestations neurologiques", "item": "https://questionsmedicales.fr/mesh/D009461" }, { "@type": "ListItem", "position": 5, "name": "Paralysie", "item": "https://questionsmedicales.fr/mesh/D010243" }, { "@type": "ListItem", "position": 6, "name": "Paralysie pseudobulbaire", "item": "https://questionsmedicales.fr/mesh/D020828" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Paralysie pseudobulbaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Paralysie pseudobulbaire", "description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Paralysie pseudobulbaire", "description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Paralysie pseudobulbaire", "description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Paralysie pseudobulbaire", "description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Paralysie pseudobulbaire", "description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Paralysie pseudobulbaire", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=9#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions." } }, { "@type": "Question", "name": "Quels symptômes aident au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole." } }, { "@type": "Question", "name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC." } }, { "@type": "Question", "name": "Peut-on confondre cette paralysie avec d'autres troubles ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables." } }, { "@type": "Question", "name": "La difficulté à parler est-elle un symptôme courant ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix." } }, { "@type": "Question", "name": "Les patients ressentent-ils de la douleur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des variations dans les symptômes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie." } }, { "@type": "Question", "name": "Peut-on prévenir la paralysie pseudobulbaire ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider." } }, { "@type": "Question", "name": "Comment réduire le risque de paralysie pseudobulbaire ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque." } }, { "@type": "Question", "name": "Les AVC peuvent-ils être prévenus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC." } }, { "@type": "Question", "name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale." } }, { "@type": "Question", "name": "La rééducation est-elle utile ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils réduire les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles de la déglutition et des problèmes de communication." } }, { "@type": "Question", "name": "La dépression est-elle une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques d'isolement social ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients." } }, { "@type": "Question", "name": "Les complications peuvent-elles être traitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le mode de vie peut-il influencer le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC." } } ] } ] }

Sources (10000 au total)

Menopausal hormone therapy and dementia: nationwide, nested case-control study.

To assess the association between use of menopausal hormone therapy and development of dementia according to type of hormone treatment, duration of use, and age at usage.... Nationwide, nested case-control study.... Denmark through national registries.... 5589 incident cases of dementia and 55 890 age matched controls were identified between 2000 and 2018 from a population of all Danish women aged 50-60 years in 2000 with no history of dementia or cont... Adjusted hazard ratios with 95% confidence intervals for all cause dementia defined by a first time diagnosis or first time use of dementia specific medication.... Compared with people who had never used treatment, people who had received oestrogen-progestogen therapy had an increased rate of all cause dementia (hazard ratio 1.24 (95% confidence interval 1.17 to... Menopausal hormone therapy was positively associated with development of all cause dementia and Alzheimer's disease, even in women who received treatment at the age of 55 years or younger. The increas...

Endometriosis features and dienogest tolerability in women with depression: a case-control study.

Primary aim of this study was to investigate endometriosis characteristics of patients with psychiatric conditions or depression. The secondary aim was to study tolerability of dienogest in this conte... This observational case-control study included endometriosis data from patients visiting our clinic from 2015-2021. We collected information from patient charts and in phone interviews based on a stru... 344 patients fulfilled the inclusion criteria:... EM-D or EM-P had a higher prevalence of pain symptoms. This could not be attributed to differences in rASRM stage or location of endometriosis lesions. Strong primary dysmenorrhoea might predispose to...

The effect of environmental factors on precocious puberty in children: a case-control study.

Recently the prevalence of precocious puberty development is increasing among Chinese children. Proper understanding of the risk factors for precocious puberty in children is pivotal as could help to ... We matched the cases and controls by age at the ratio of 1:1 (201 cases and 201 controls) for girls and 1:4 (24 cases and 96 controls) for boys. We used conditional logistic regression to explore the ... In the multivariate regression, cesarean section (OR = 1.99, 95% CI: 1.05, 3.76), child body mass index [BMI] (OR = 1.25, 95% CI: 1.10, 1.43), maternal BMI (OR = 1.13, 95%CI: 1.01, 1.26), and exposure... Our findings suggest that environmental factors were associated with precocious puberty in children, particularly in girls....

Neonatal Group B Streptococcal Infection in Australia: A Case-control Study.

To determine maternal and neonatal risk factors for, and incidence of, neonatal early-onset group B streptococcus (EOGBS) and late-onset (LOGBS) infection in South Australia (SA) and the Northern Terr... A case-control study with 2:1 matched controls to cases. The study included tertiary hospitals in South Australia and the Northern Territory, Australia. Retrospective data were collected from a 16-yea... Of a total of 188 clinically suspected or confirmed cases, 139 were confirmed, of which 56.1% (n = 78) were EOGBS and 43.9% (n = 61) were LOGBS. The incidence of clinically suspected and confirmed cas... GBS remains a leading cause of neonatal morbidity and mortality. Adding previous fetal death to GBS screening guidelines would improve GBS prevention. The introduction of maternal GBS vaccination prog...

Topological Structural Brain Connectivity Alterations in Aspartylglucosaminuria: A Case-Control Study.

We investigated global and local properties of the structural brain connectivity networks in aspartylglucosaminuria, an autosomal recessive and progressive neurodegenerative lysosomal storage disease.... We acquired diffusion MR imaging and T1-weighted data from 12 patients with aspartylglucosaminuria (mean age, 23 [SD, 8] years; 5 men), and 30 healthy controls (mean age, 25 [SD, 10] years; 13 men). W... The integration of the networks was decreased, as demonstrated by a decreased normalized global efficiency and an increased normalized characteristic path length. In addition, the average strength of ... We found global and local structural connectivity alterations in aspartylglucosaminuria. Biomarkers related to the treatment efficacy are needed, and brain network properties may provide the means for...

Predictive plasma biomarker for gestational diabetes: A case-control study in China.

This study aims to find new plasma biomarkers in early pregnancy.... The original study enrolled 1219 pregnant women. We investigated protein expression profiles of placental tissues from women with GDM (n = 89) and normal glucose tolerance (NGT) (n = 83). Maternal pla... Differentially expressed proteins (DEPs) were identified by label-free quantitative proteomics from human placenta samples between two groups. Several DEPs were validated in plasma by Luminex assays. ... 123 DEPs were found in placenta involved in ribosomal function, pancreatic secretion, oxidative phosphorylation, and inflammatory signaling pathway. Plasma GAL-3BP are significantly higher in women wi... Plasma TG and GAL-3BP has good predictive and diagnostic value at early pregnancy, suggesting that these two indicators may be used as biomarkers for early prediction and diagnosis of GDM.... The advantage of this study is that circulating TG and GAL-3BP might differentiate the progress of women with GDM and normal glucose tolerance (NGT) at the early stage of pregnancy. It is the first st...

Familial aggregation of stillbirth: A pedigree analysis of a matched case-control study.

To determine whether stillbirth aggregates in families and quantify its familial risk using extended pedigrees.... State-wide matched case-control study.... Utah, United States.... Stillbirth cases (n = 9404) and live birth controls (18 808) between 1978 and 2019.... Using the Utah Population Database, a population-based genealogical resource linked with state fetal death and birth records, we identified high-risk pedigrees with excess familial aggregation of stil... Familial aggregation estimated using FSIR, and stillbirth OR estimated for FDR, SDR and TDR of affected and unaffected parents using logistic regression models.... We identified 390 high-risk pedigrees with evidence for excess familial aggregation (FSIR ≥2.00; P-value <0.05). FDRs, SDRs and TDRs of affected parents had 1.14-fold (95% confidence interval [CI]: 1.... We provide evidence for familial aggregation of stillbirth. Our findings warrant investigation into genes associated with stillbirth and underscore the need to design large-scale studies to determine ...